Neurocrine Biosciences, Inc. NBIX
At closeNov 6, 2026, 4:25 AM EST
Pre-market · Nov 6, 4:25 AM ET
- YTD
- +12.64%
- 1 year
- +3.20%
- Market cap
- 16.17B
- Revenue (ttm)
- 3.70B
- Profit margin
- 18.98%
- EPS (ttm)
- 6.74
- Shares out
- 101.22M
- P/E ratio
- 23.70
- Forward P/E
- 13.87
- YTD return
- +12.64%
- 1-year return
- +3.20%
- Volume
- 1.48M
- Avg volume
- 1.31M
- Open
- 167.68
- Previous close
- 166.05
- Day's range
- 159.53 – 167.68
- 52-week range
- 122.14 – 186.12
- Beta
- 0.33
- Analysts
- Strong Buy
- Price target
- 207.50 (+29.9%)
- Earnings date
- Feb 10, 2027
5D +11.68 (+7.89%)
Key statistics
- Enterprise value
- 16.40B
- PEG ratio
- 0.34
- Price / sales
- 4.54
- Price / book
- 4.34
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 41.20%
- Free cash flow
- 1.02B
- Total cash
- 737.90M
- Total debt
- 451.80M
- Return on equity
- 20.41%
- Short % of float
- 8.27%
- 50-day average
- 146.72
- 200-day average
- 147.60
Analyst view
Consensus: strong buy
- Target (low)
- 150.00
- Target (mean)
- 207.50
- Target (high)
- 253.00
- Strong buy4
- Buy21
- Hold4
- Sell0
- Strong sell0
Next earnings
Feb 10, 2027
Expected Feb 10, 2027. Consensus EPS estimate 2.75.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 10, 2027 | Dec 30, 2026 | 2.07 | — | — | — |
| Nov 2, 2026 | Sep 30, 2026 | 1.91 | 3.29 | +1.38 | +72.25% |
| Jul 30, 2026 | Jun 30, 2026 | 1.85 | 2.85 | +1.00 | +54.05% |
| May 5, 2026 | Mar 31, 2026 | 1.22 | 1.91 | +0.69 | +56.56% |
| Feb 11, 2026 | Dec 31, 2025 | 1.80 | 1.88 | +0.08 | +4.44% |
| Oct 28, 2025 | Sep 30, 2025 | 1.58 | 2.04 | +0.46 | +29.11% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 4, 2026 | Guggenheim | main | Buy | Buy |
| Nov 3, 2026 | Morgan Stanley | main | Equal-Weight | Equal-Weight |
| Nov 3, 2026 | RBC Capital | main | Outperform | Outperform |
| Nov 3, 2026 | Canaccord Genuity | main | Buy | Buy |
| Nov 3, 2026 | Piper Sandler | main | Overweight | Overweight |
| Oct 16, 2026 | Needham | reit | Buy | Buy |
About Neurocrine Biosciences, Inc.
Neurocrine Biosciences, Inc. discovers, develops, and commercialize pharmaceuticals for neurological, psychiatric, endocrine, and immunological disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; Orilissa tablets for endometriosis; Oriahnn capsules to treat uterine fibroids; and CRENESSITY to treat congenital adrenal hyperplasia, as well as offers products under the name of ALKINDI and Efmody. Its product candidates in clinical development includes NBI-1076986 to treat movement disorders; Osavampator for inadequate response to treatment in major depressive disorder; NBI-1117568 for the treatment of schizophrenia and bipolar mania; NBI-1117567 for the treatment of Alzheimer's disease; NBI 921355 for the treatment of epilepsy; NBIP-01435 for the treatment of congenital adrenal hyperplasia; NBIP-2118 for the treatment of obesity and related metabolic diseases; and NBI-1070770 to treat major depressive disorder; and NBI-1117570, NBI-1117567, NBI-1117569, NBI-1140675, and NBI-1065890 for neuropsychiatric and neurological conditions. The company also has license and collaboration agreements with Nxera Pharma UK Limited; Takeda Pharmaceutical Company Limited; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; Sanofi S.A.; Tanabe Pharma Corporation; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Country
- United States
- Website
- neurocrine.com
News
Neurocrine Biosciences Releases Findings From New Survey Showing Adults With Tardive Dyskinesia Reported Fewer Disruptions To Work, School After Starting Treatment With INGREZZA Capsules 
Neurocrine Biosciences Presents New Tardive Dyskinesia Survey Results Showing Fewer Work and School Disruptions with INGREZZA® (valbenazine) Capsules 
Neurocrine Biosciences, Inc. $NBIX Shares Newly Bought by Factory Mutual Insurance Co. 
Neurocrine Biosciences: Breaking Down A Solid Quarter 
Guggenheim Maintains Buy on Neurocrine Biosciences, Raises Price Target to $224 
Neurocrine Biosciences: 3 Growth Drivers And An Attractive Valuation 
Neurocrine Biosciences: Up 15% After Q3, And The Research Engine Is Still Almost Free 
Neurocrine Biosciences (NASDAQ:NBIX) Stock Price Breaks Above Two Hundred Day Moving Average on Insider Selling 
Neurocrine Biosciences to Spotlight Its Scientific Journey and Growing Neuropsychiatry Pipeline at 2026 NEI Fall Congress 
Morgan Stanley Maintains Equal-Weight on Neurocrine Biosciences, Raises Price Target to $185
Your note
Sign in to keep a note on NBIX — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ABERNETHY MATTHEW C | Chief Financial Officer | Sale | Sep 13, 2026 | 42,808 |
| BENEVICH ERIC S. | Officer | Stock Award(Grant) | Sep 10, 2026 | 67,297 |
| COOKE JULIE SMITH | Officer | Stock Award(Grant) | Sep 10, 2026 | 24,025 |
| GANO KYLE W | Chief Executive Officer | Conversion of Exercise of derivative security | Oct 29, 2026 | 155,010 |
| GORMAN KEVIN CHARLES | Director | Stock Award(Grant) | Sep 10, 2026 | 517,797 |
| LIPPOLDT DARIN M | Officer | Stock Award(Grant) | Sep 10, 2026 | 56,793 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 13.55% | 13,711,607 | 2.28B | Jun 29, 2026 |
| JPMORGAN CHASE & CO | 6.32% | 6,398,674 | 1.06B | Jun 29, 2026 |
| Dodge & Cox Inc. | 5.52% | 5,584,707 | 927.34M | Jun 29, 2026 |
| Vanguard Portfolio Management LLC | 4.91% | 4,974,083 | 825.95M | Jun 29, 2026 |
| Vanguard Capital Management LLC | 4.49% | 4,545,339 | 754.75M | Jun 29, 2026 |
| State Street Corporation | 4.33% | 4,385,598 | 728.23M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Dodge & Cox Funds-Dodge & Cox Stock Fund | 3.92% | 3,964,000 | 658.22M | Jun 29, 2026 |
| iShares Trust-iShares Core S&P Mid-Cap ETF | 3.58% | 3,620,760 | 601.23M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 3.15% | 3,193,267 | 530.24M | Jun 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund | 2.28% | 2,304,996 | 382.74M | Jun 29, 2026 |
| J.P. Morgan Mutual Fd. Investment TRT-JPMorgan Growth Advantage Fd. | 1.34% | 1,358,475 | 225.57M | Jun 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Growth Index Fund | 1.31% | 1,329,829 | 220.82M | Jun 29, 2026 |